Product Description: GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates[1][2].
Applications: COVID-19-immunoregulation
Formula: C11H22N6O
References: [1]Golder FJ, et al. Identification and Characterization of GAL-021 as a Novel Breathing Control Modulator. Anesthesiology. 2015 Nov;123(5):1093-104./[2]J F McLeod, et al. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. Br J Anaesth. 2014 Nov;113(5):875-83.
CAS Number: 1380341-99-0
Molecular Weight: 254.33
Compound Purity: 99.89
Research Area: Inflammation/Immunology
Solubility: DMSO : ≥ 30 mg/mL
Target: Potassium Channel
English
Deutsch
